Abstract
Personalized medicine and precision medicine are presenting new opportunities for better patient care, but also present unique challenges. The traditional randomized clinical trial is not necessarily the most appropriate approach to evaluating what may be the best treatment for an individual. Alternative study designs pose unique regulatory challenges for the U.S. Food and Drug Administration but offer the opportunity for higher response rates. Ovarian stimulation for assisted reproductive technology offers opportunities for personalized and more precise approaches to individual patient care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
